Find Dabrafenib Mesylate manufacturers, exporters & distributors on PharmaCompass

PharmaCompass

Synopsis

Synopsis

ACTIVE PHARMA INGREDIENTS

0

CEP/COS

0

JDMF

0

EU WC

0

KDMF

0

VMF

REF. STANDARDS OR IMPURITIES

0

EDQM

0

USP

0

JP

0

Others

GLOBAL SALES INFORMATION

Regulatory FDF Prices

NA

MARKET PLACE

DIGITAL CONTENT

0

Data Compilation #PharmaFlow

0

Stock Recap #PipelineProspector

0

Weekly News Recap #Phispers

Chemistry

Click the arrow to open the dropdown
read-moreClick the button for full data set
Also known as: 1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e
Molecular Formula
C24H24F3N5O5S3
Molecular Weight
615.7  g/mol
InChI Key
YKGMKSIHIVVYKY-UHFFFAOYSA-N
FDA UNII
B6DC89I63E

Dabrafenib Mesylate
Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.
1 2D Structure

Dabrafenib Mesylate

2 Identification
2.1 Computed Descriptors
2.1.1 IUPAC Name
N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic acid
2.1.2 InChI
InChI=1S/C23H20F3N5O2S2.CH4O3S/c1-23(2,3)21-30-18(19(34-21)16-10-11-28-22(27)29-16)12-6-4-9-15(17(12)26)31-35(32,33)20-13(24)7-5-8-14(20)25;1-5(2,3)4/h4-11,31H,1-3H3,(H2,27,28,29);1H3,(H,2,3,4)
2.1.3 InChI Key
YKGMKSIHIVVYKY-UHFFFAOYSA-N
2.1.4 Canonical SMILES
CC(C)(C)C1=NC(=C(S1)C2=NC(=NC=C2)N)C3=C(C(=CC=C3)NS(=O)(=O)C4=C(C=CC=C4F)F)F.CS(=O)(=O)O
2.2 Other Identifiers
2.2.1 UNII
B6DC89I63E
2.3 Synonyms
2.3.1 Depositor-Supplied Synonyms

1. 1195768-06-9

2. Dabrafenib (mesylate)

3. Gsk 2118436b

4. Dabrafenib Mesilate

5. Dabrafenib Mesylate [usan]

6. Unii-b6dc89i63e

7. Gsk-2118436 Mesylate

8. Gsk-2118436b

9. Methane Sulfonate Salt

10. Gsk2118436b

11. Gsk2118436 Mesylate

12. B6dc89i63e

13. Chebi:75048

14. Gsk-2118436b Mesylate

15. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(tert-butyl)thiazol-4-yl)-2-fluorophenyl)-2,6-difluorobenzenesulfonamide Methanesulfonate

16. Gsk2118436b, Methane Sulfonate Salt

17. Gsk-2118436 Methanesulfonate Salt

18. Gsk-2118436b Methanesulfonate Salt

19. Gsk2118436 Mesylate;gsk 2118436b

20. Dabrafenib Mesilate (jan)

21. Dabrafenib Mesylate (gsk-2118436)

22. Dabrafenib Mesylate (usan)

23. Dabrafenib Mesilate [jan]

24. Taflinar

25. N-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide;methanesulfonic Acid

26. Dabrafenib Methanesulfonate

27. Tafinlar (tn)

28. Gsk2118436 Methane Sulfonate Salt

29. Dabrafenib Monomesylate

30. Gsk 2118436 Mesylate

31. Schembl1127269

32. Chembl2105729

33. Dabrafenib Mesylate [mi]

34. Dtxsid70152500

35. Amy30045

36. Bcp04738

37. Ex-a1559

38. Dabrafenib Mesilate [who-dd]

39. Hy-14660a

40. Mfcd20922872

41. S5069

42. Akos025396661

43. Ccg-270246

44. Cs-1641

45. Dabrafenib Mesylate [orange Book]

46. Ac-31302

47. As-17010

48. Ft-0696677

49. D10104

50. A903491

51. Sr-01000941590

52. Sr-01000941590-1

53. Q27145089

54. Gsk2118436 Ms Salt, Dabrafenib Ms Salt, Gsk2118436a Ms Salt

55. Benzenesulfonamide, N-(3-(5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl)- 2-fluorophenyl)-2,6-difluoro-, Methanesulfonate (1:1)

56. Benzenesulfonamide, N-[3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-4-thiazolyl]-2-fluorophenyl]-2,6-difluoro-, Methanesulfonate (1:1)

57. Dabrafenib Mesylaten-[3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl]-2,6-difluorobenzenesulfonamide, Methanesulfonic Acid; Dabrafenib Mesylate

58. N-(3-(5-(2-aminopyrimidin-4-yl)-2-(1,1-dimethylethyl)thiazol-4-yl)-2-fluorophenyl)-2,6- Difluorobenzenesulfonamide Monomethanesulfonate

59. N-{3-[5-(2-amino-4-pyrimidinyl)-2-(1,1-dimethylethyl)-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

60. N-{3-[5-(2-aminopyrimidin-4-yl)-2-tert-butyl-1,3-thiazol-4-yl]-2-fluorophenyl}-2,6-difluorobenzenesulfonamide Methanesulfonate

2.3.2 Other Synonyms

1. 1195765-45-7

2. Dabrafenib

2.4 Create Date
2009-12-22
3 Chemical and Physical Properties
Molecular Weight 615.7 g/mol
Molecular Formula C24H24F3N5O5S3
Hydrogen Bond Donor Count3
Hydrogen Bond Acceptor Count14
Rotatable Bond Count6
Exact Mass615.08916689 g/mol
Monoisotopic Mass615.08916689 g/mol
Topological Polar Surface Area210 Ų
Heavy Atom Count40
Formal Charge0
Complexity910
Isotope Atom Count0
Defined Atom Stereocenter Count0
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Covalently Bonded Unit Count2
4 Drug and Medication Information
4.1 Drug Indication

* Melanoma:

Dabrafenib as monotherapy or in combination with trametinib is indicated for the treatment of adult patients with unresectable or metastatic melanoma with a BRAF V600 mutation (see sections 4. 4 and 5. 1).

* Adjuvant treatment of melanoma:

Dabrafenib in combination with trametinib is indicated for the adjuvant treatment of adult patients with Stage III melanoma with a BRAF V600 mutation, following complete resection.

* Non-small cell lung cancer (NSCLC):

Dabrafenib in combination with trametinib is indicated for the treatment of adult patients with advanced non-small cell lung cancer with a BRAF V600 mutation.


Treatment of melanoma, Treatment of solid malignant tumours (excluding melanoma)


5 Pharmacology and Biochemistry
5.1 ATC Code

L01EC02


Listed Suppliers

read-more
read-more

01

Fermion Oy

Finland
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothWith Fermion, start the journey of your innovative API.

Flag Finland
Digital Content Digital Content

Dabrafenib

About the Company : Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio inc...

Fermion, a wholly owned subsidiary of Orion Corporation and headquartered in Espoo, Finland, is a fully integrated CDMO offering API and formulation services. Its API portfolio includes over 30 generic APIs and more than 10 NCEs, with two manufacturing sites and R&D facilities in Finland. Fermion has expanded capabilities in HPAPI production. Drug product CMO services cover hormonal and non-hormonal semi-solids, cytotoxic oral solids, and packaging, supported by three manufacturing sites and one packaging center under Orion. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
fermion

02

Seqens

France
  • fda
  • EDQM
  • WHO-GMP

Virtual BoothSeqens is an integrated global leader in pharmaceutical solutions & specialty ingredients, & custom-made solutions to our customers.

Flag France
Digital Content Digital Content

Dabrafenib Mesylate

About the Company : Founded in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. The company supports customers in the development, scale-up, and man...

Founded in 2003, Seqens has evolved into a global leader in pharmaceutical solutions and specialty ingredients. The company supports customers in the development, scale-up, and manufacturing of drug substances from pre-clinical to commercial stages. Seqens offers a broad portfolio of APIs and proprietary products, along with custom solutions for healthcare, electronics, and cosmetics. With 15 industrial plants and 5 R&D centers worldwide, Seqens produces complex molecules across small- and large-scale requirements. Note: Product(s) under patent(s) are offered only for R&D purposes as per the Patent Act & not for commercial sale.
Seqens Company Banner

03

  • fda
  • EDQM
  • WHO-GMP

Virtual BoothTAPI, a leading global supplier of APIs, provides over 350 products and customized CDMO solutions for every stage of development.

Flag Israel
Digital Content Digital Content

Dabrafenib Mesylate

About the Company : Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios ...

Founded in 1935, TAPI Technology & API Services has a long legacy of advancing health through innovation. Today, we offer one of the industry’s most comprehensive API portfolios with over 350 products, alongside tailored CDMO services. Leveraging deep expertise and diverse technologies, we deliver flexible, high-quality solutions to meet our partners’ needs. Note: None of the products will be supplied to countries in which this could be in conflict with existing patents. Further, any products under patent will be offered for R&D purposes only. However, the final responsibility lies with the buyer.
TAPI Company Banner

04

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Dabrafenib Mesylate

About the Company : Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutica...

Alembic Pharmaceuticals Limited is a leading pharmaceutical company in India. The Company is vertically integrated with the ability to develop, manufacture and market pharmaceutical products, pharmaceutical substances and Intermediates.
blank

05

Aspen Bio

India
Bioprocess International Europe
Not Confirmed
arrow

Aspen Bio

India
arrow
Bioprocess International Europe
Not Confirmed

Dabrafenib Mesylate

About the Company : Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health servic...

Aspen Bio is a multifaceted company that was established in 2014. Aspen Bio defines development and novelty as a challenge for competitive markets to provide improved health services to people, through pioneering Research & Development in agreement with the latest principles to ensure safe and secured wellness. The Company is established in bringing the benefit of high quality APIs & Finished Formulations, yet reasonably priced, to patients in India and other emerging markets.
blank

06

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Dabrafenib

About the Company : Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, o...

Daishang Chemical Co., Ltd. established in January 2005, sticking to the guiding principle "Technical innovation, Quality Orientation", we practice best of technology innovation, optimized management and robust service system for our customers. Daishang Chem is specialized in the researching, manufacturing, sales and marketing of API & Its Intermediates as well as other Fine Chemicals, taking great advantages of professional and proficient staff, based on three chemical manufacturing sites and one GMP manufacturing workshops in Liaoning, Henan and Zhejiang provinces, and one R&D laboratory in Zhangjiang Hi-tech Park.
blank

07

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

dabrafenib

About the Company : Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients an...

Established in August 2011, Raffles PharmaTech is a high-tech enterprise that focus on development, manufacturing and sales of high-value added active pharmaceutical ingredients and intermediates. We are specialized in applying organic catalysts into the process development to lower cost, and to provide cost-effective product and service to customers. With our strong R&D capability and our proprietary organic catalysts, we provide low cost and high quality active pharmaceutical ingredients and intermediates to pharmaceutical companies. We also provide world standard process development, custom synthesis and manufacturing service.
blank

08

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

dabrafenib

About the Company : Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, cat...

Established in 2011 and situated in Hangzhou, Zhejiang, China, Hangzhou Longshine Bio-Tech CO., Ltd is dedicated to providing services for pharmaceutical and chemical products, catering to both export and import markets. The company consists of two primary business departments: the Professional Sourcing/Product Team and the Quality Team. Backed by experienced partners, Longshine has evolved into a trustworthy supplier of high-quality products and received ISO9001:2008 certification in 2017.
blank

09

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Dabrafenib Mesylate

About the Company : Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing p...

Consistent growth and sustainability is a multidimensional aspiration for all at Macleods, we remained focused on providing quality and affordable medicines to billions of ailing patients across geographies and bridging the gap of unmet needs of medical fraternity through continuous innovation. Our basic business philosophy, by its very nature, serves a social responsibility hence we have a far better reason than profits alone to drive our performance. Sustainability, is not a trend we blindly follow, it is intrinsic to how we have operated since the genesis of the organization in the year 1986.
blank

10

Bioprocess International Europe
Not Confirmed
arrow
arrow
Bioprocess International Europe
Not Confirmed

Dabrafenib Mesylate

About the Company : Parsian Pharmaceutical is dedicated to improving health outcomes by offering high-quality, effective pharmaceutical products. With a strong commitment to research, innovation, and ...

Parsian Pharmaceutical is dedicated to improving health outcomes by offering high-quality, effective pharmaceutical products. With a strong commitment to research, innovation, and quality, Parsian Pharmaceutical develops and manufactures a broad range of medications designed to meet international standards and address diverse therapeutic needs. Serving both local and global markets, Parsian Pharmaceutical strives to be a trusted healthcare partner, providing reliable, accessible solutions that enhance patient care and contribute to a healthier society.
blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

Drugs in Development

read-more
read-more
  • Development Update

Details:

Tafinlar (Dabrafenib Mesylate) is a small molecule drug, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of hematologic neoplasms.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Tafinlar

Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable February 27, 2026

blank

01

Cancer Research UK

Country
arrow
Bioprocess International Europe
Not Confirmed

Cancer Research UK

Country
arrow
Bioprocess International Europe
Not Confirmed

Details : Tafinlar (Dabrafenib Mesylate) is a small molecule drug, which is currently being evaluated in Phase II/ Phase III clinical studies for the treatment of hematologic neoplasms.

Product Name : Tafinlar

Product Type : Miscellaneous

Upfront Cash : Inapplicable

February 27, 2026

blank
  • Development Update

Details:

Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Carcinoma, Anaplastic.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Novartis Pharmaceuticals Corporation

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable October 12, 2023

blank

02

Leiden University Medical Center

Country
arrow
Bioprocess International Europe
Not Confirmed

Leiden University Medical Center

Country
arrow
Bioprocess International Europe
Not Confirmed

Details : Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Carcinoma, Anaplastic.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

October 12, 2023

blank

Details:

Tafinlar is a combination of dabrafenib mesylate and trametinib that targets two different kinases in the RAS/RAF/MEK/ERK pathway. This combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Tafinlar

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable March 16, 2023

blank

03

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Tafinlar is a combination of dabrafenib mesylate and trametinib that targets two different kinases in the RAS/RAF/MEK/ERK pathway. This combination resulted in greater growth inhibition of BRAF V600 mutation-positive tumor cell lines.

Product Name : Tafinlar

Product Type : Miscellaneous

Upfront Cash : Inapplicable

March 16, 2023

blank

Details:

JSI-1187 is a selective and orally administered small molecule inhibitor of ERK1 and ERK2. In preclinical studies, JSI-1187 demonstrated high potency against a variety of tumors with MAPK pathway mutations.


Lead Product(s): JSI-1187,Dabrafenib Mesylate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 03, 2023

blank

04

JS InnoPharm

China
arrow
Bioprocess International Europe
Not Confirmed

JS InnoPharm

China
arrow
Bioprocess International Europe
Not Confirmed

Details : JSI-1187 is a selective and orally administered small molecule inhibitor of ERK1 and ERK2. In preclinical studies, JSI-1187 demonstrated high potency against a variety of tumors with MAPK pathway mutations.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 03, 2023

blank

Details:

E6201 is an ATP-competitive MEK1 inhibitor that has demonstrated preclinical activity in BRAF V600-mutant melanoma cell lines. E6201 has shown excellent brain distribution characteristics and minimal CNS efflux by transporters at the BBB.


Lead Product(s): E6201,Dabrafenib Mesylate

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable November 30, 2022

blank

05

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : E6201 is an ATP-competitive MEK1 inhibitor that has demonstrated preclinical activity in BRAF V600-mutant melanoma cell lines. E6201 has shown excellent brain distribution characteristics and minimal CNS efflux by transporters at the BBB.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

November 30, 2022

blank

Details:

Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Craniopharyngioma.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Eva Marie Erfurth

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable September 01, 2022

blank

06

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Craniopharyngioma.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

September 01, 2022

blank

Details:

FDA approval was based on clinical efficacy and safety demonstrated in three clinical trials. In Phase II ROAR basket study and NCI-MATCH Subprotocol H study, Tafinlar (dabrafenib mesylate) + Mekinist resulted in overall response rates of up to 80% in patients with BRAF V600E.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Tafinlar

Study Phase: Approved FDFProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 23, 2022

blank

07

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : FDA approval was based on clinical efficacy and safety demonstrated in three clinical trials. In Phase II ROAR basket study and NCI-MATCH Subprotocol H study, Tafinlar (dabrafenib mesylate) + Mekinist resulted in overall response rates of up to 80% in pa...

Product Name : Tafinlar

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 23, 2022

blank

Details:

Treatment with targeted therapies Tafinlar (dabrafenib)+ Mekinist resulted in 47% ORR versus chemotherapy and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients with BRAF V600 LGG requiring first systemic treatment.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Tafinlar

Study Phase: Phase II/ Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 06, 2022

blank

08

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Treatment with targeted therapies Tafinlar (dabrafenib)+ Mekinist resulted in 47% ORR versus chemotherapy and reduced risk of progression or death by 69%, showing significant efficacy improvement in patients with BRAF V600 LGG requiring first systemic tr...

Product Name : Tafinlar

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 06, 2022

blank
  • Development Update

Details:

Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Neoplasms.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIProduct Type: Miscellaneous

Sponsor: Royal North Shore Hospital | Austin Health | Sir Charles Gairdner Hospital | Monash Health | Peter MacCallum Cancer Centre | Royal Brisbane and Women's Hospital | Eastern Health | The Alfred | Royal Adelaide Hospital

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable January 10, 2022

blank

09

Olivia Newton-John Cancer Research Institute

Country
arrow
Bioprocess International Europe
Not Confirmed

Olivia Newton-John Cancer Research Institute

Country
arrow
Bioprocess International Europe
Not Confirmed

Lead Product(s) : Dabrafenib Mesylate,Trametinib

Therapeutic Area : Oncology

Highest Development Status : Phase II

Partner/Sponsor/Collaborator : Royal North Shore Hospital | Austin Health | Sir Charles Gairdner Hospital | Monash Health | Peter MacCallum Cancer Centre | Royal Brisbane and Women's Hospital | Eastern Health | The Alfred | Royal Adelaide Hospital

Deal Size : Inapplicable

Deal Type : Inapplicable

Details : Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Thyroid Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

January 10, 2022

blank

Details:

Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thyroid Neoplasms.


Lead Product(s): Dabrafenib Mesylate,Trametinib

Therapeutic Area: Oncology Brand Name: Undisclosed

Study Phase: Phase IIIProduct Type: Miscellaneous

Sponsor: Undisclosed

Deal Size: Inapplicable Upfront Cash: Inapplicable

Deal Type: Inapplicable June 25, 2021

blank

10

Bioprocess International Europe
Not Confirmed
Bioprocess International Europe
Not Confirmed

Details : Dabrafenib is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Thyroid Neoplasms.

Product Name : Undisclosed

Product Type : Miscellaneous

Upfront Cash : Inapplicable

June 25, 2021

blank
click full view
Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]

DRUG PRODUCT COMPOSITIONS

Do you need Business Intel? Ask us

DOSAGE - CAPSULE;ORAL - EQ 50MG BASE

USFDA APPLICATION NUMBER - 202806

read-more

DOSAGE - CAPSULE;ORAL - EQ 75MG BASE

USFDA APPLICATION NUMBER - 202806

read-more

Related Excipient Companies

Upload your portfolio for free, ask us

Excipients by Applications

Click here to find the perfect excipient manufacturers by their capabilities

Coating Systems & Additives

read-more
read-more

Fillers, Diluents & Binders

read-more
read-more

Controlled & Modified Release

read-more
read-more

Thickeners and Stabilizers

read-more
read-more

Lubricants & Glidants

read-more
read-more

Direct Compression

read-more
read-more

Co-Processed Excipients

read-more
read-more

Granulation

read-more
read-more

Film Formers & Plasticizers

read-more
read-more

Empty Capsules

read-more
read-more

Disintegrants & Superdisintegrants

read-more
read-more

Emulsifying Agents

read-more
read-more

Chewable & Orodispersible Aids

read-more
read-more

Vegetarian Capsules

read-more
read-more

Taste Masking

read-more
read-more

API Stability Enhancers

read-more
read-more

Coloring Agents

read-more
read-more

Rheology Modifiers

read-more
read-more

Solubilizers

read-more
read-more

Digital Content read-more

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

Global Sales Information

Do you need Business Intel? Ask us

Market Place

Do you need sourcing support? Ask us

Patents & EXCLUSIVITIES

Check the patents & exclusivity for this product

ABOUT THIS PAGE

Looking for 1195768-06-9 / Dabrafenib Mesylate API manufacturers, exporters & distributors?

Dabrafenib Mesylate manufacturers, exporters & distributors 1

68

PharmaCompass offers a list of Dabrafenib Mesylate API manufacturers, exporters & distributors, which can be sorted by GMP, USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dabrafenib Mesylate manufacturer or Dabrafenib Mesylate supplier for your needs.

Send us enquiries for free, and we will assist you in establishing a direct connection with your preferred Dabrafenib Mesylate manufacturer or Dabrafenib Mesylate supplier.

API | Excipient name

Dabrafenib Mesylate

Synonyms

1195768-06-9, Dabrafenib (mesylate), Gsk 2118436b, Dabrafenib mesilate, Dabrafenib mesylate [usan], Unii-b6dc89i63e

Cas Number

1195768-06-9

Unique Ingredient Identifier (UNII)

B6DC89I63E

About Dabrafenib Mesylate

Dabrafenib Mesylate is the mesylate salt form of dabrafenib, an orally bioavailable inhibitor of B-raf (BRAF) protein with potential antineoplastic activity. Dabrafenib selectively binds to and inhibits the activity of B-raf, which may inhibit the proliferation of tumor cells which contain a mutated BRAF gene. B-raf belongs to the raf/mil family of serine/threonine protein kinases and plays a role in regulating the MAP kinase/ERKs signaling pathway, which may be constitutively activated due to BRAF gene mutations.

Dabrafenib Mesylate Manufacturers

A Dabrafenib Mesylate manufacturer is defined as any person or entity involved in the manufacture, preparation, processing, compounding or propagation of Dabrafenib Mesylate, including repackagers and relabelers. The FDA regulates Dabrafenib Mesylate manufacturers to ensure that their products comply with relevant laws and regulations and are safe and effective to use. Dabrafenib Mesylate API Manufacturers are required to adhere to Good Manufacturing Practices (GMP) to ensure that their products are consistently manufactured to meet established quality criteria.

click here to find a list of Dabrafenib Mesylate manufacturers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PhamaCompass.

Dabrafenib Mesylate Suppliers

A Dabrafenib Mesylate supplier is an individual or a company that provides Dabrafenib Mesylate active pharmaceutical ingredient (API) or Dabrafenib Mesylate finished formulations upon request. The Dabrafenib Mesylate suppliers may include Dabrafenib Mesylate API manufacturers, exporters, distributors and traders.

click here to find a list of Dabrafenib Mesylate suppliers with USDMF, JDMF, KDMF, CEP, GMP, and COA related information on PharmaCompass.

Dabrafenib Mesylate USDMF

A Dabrafenib Mesylate DMF (Drug Master File) is a document detailing the whole manufacturing process of Dabrafenib Mesylate active pharmaceutical ingredient (API) in detail. Different forms of Dabrafenib Mesylate DMFs exist exist since differing nations have different regulations, such as Dabrafenib Mesylate USDMF, ASMF (EDMF), JDMF, CDMF, etc.

A Dabrafenib Mesylate DMF submitted to regulatory agencies in the US is known as a USDMF. Dabrafenib Mesylate USDMF includes data on Dabrafenib Mesylate's chemical properties, information on the facilities and procedures used, and details about packaging and storage. The Dabrafenib Mesylate USDMF is kept confidential to protect the manufacturer’s intellectual property.

click here to find a list of Dabrafenib Mesylate suppliers with USDMF on PharmaCompass.

Dabrafenib Mesylate NDC

National Drug Code is a comprehensive database maintained by the FDA that contains information on all drugs marketed in the US. This directory includes information about finished drug products, unfinished drug products, and compounded drug products, including those containing Dabrafenib Mesylate as an active pharmaceutical ingredient (API).

Finished drug products

The FDA updates the NDC directory daily. The NDC numbers for Dabrafenib Mesylate API and other APIs are published in this directory by the FDA.

Unfinished drugs

The NDC unfinished drugs database includes product listing information submitted for all unfinished drugs, such as active pharmaceutical ingredients (APIs), drugs intended for further processing and bulk drug substances for compounding.

Pharmaceutical companies that manufacture Dabrafenib Mesylate as an active pharmaceutical ingredient (API) must furnish the FDA with an updated record of all drugs that they produce, prepare, propagate, compound, or process for commercial distribution in the US at their facilities.

Compounded drug products

The NDC directory also contains data on finished compounded human drug products that contain Dabrafenib Mesylate and are produced by outsourcing facilities. While these outsourcing facilities are not mandated to assign a Dabrafenib Mesylate NDC to their finished compounded human drug products, they may choose to do so.

click here to find a list of Dabrafenib Mesylate suppliers with NDC on PharmaCompass.

Dabrafenib Mesylate GMP

Dabrafenib Mesylate Active pharmaceutical ingredient (API) is produced in GMP-certified manufacturing facility.

GMP stands for Good Manufacturing Practices, which is a system used in the pharmaceutical industry to make sure that goods are regularly produced and monitored in accordance with quality standards. The FDA’s current Good Manufacturing Practices requirements are referred to as cGMP or current GMP which indicates that the company follows the most recent GMP specifications. The World Health Organization (WHO) has its own set of GMP guidelines, called the WHO GMP. Different countries can also set their own guidelines for GMP like China (Chinese GMP) or the EU (EU GMP).

PharmaCompass offers a list of Dabrafenib Mesylate GMP manufacturers, exporters & distributors, which can be sorted by USDMF, JDMF, KDMF, CEP (COS), WC, and more, enabling you to easily find the right Dabrafenib Mesylate GMP manufacturer or Dabrafenib Mesylate GMP API supplier for your needs.

Dabrafenib Mesylate CoA

A Dabrafenib Mesylate CoA (Certificate of Analysis) is a formal document that attests to Dabrafenib Mesylate's compliance with Dabrafenib Mesylate specifications and serves as a tool for batch-level quality control.

Dabrafenib Mesylate CoA mostly includes findings from lab analyses of a specific batch. For each Dabrafenib Mesylate CoA document that a company creates, the USFDA specifies specific requirements, such as supplier information, material identification, transportation data, evidence of conformity and signature data.

Dabrafenib Mesylate may be tested according to a variety of international standards, such as European Pharmacopoeia (Dabrafenib Mesylate EP), Dabrafenib Mesylate JP (Japanese Pharmacopeia) and the US Pharmacopoeia (Dabrafenib Mesylate USP).

Inform the supplier about your product requirements, specifying if you need a product with particular monograph like EP (Ph. Eur.), USP, JP, BP, or any other quality. In addition, clarify whether you need hydrochloride (HCl), anhydricum, base, micronisatum or a specific level of purity. To find reputable suppliers, utilize the filters and select those certified by GMP, FDA, or any other certification as per your requirement.
For your convenience, we have listed synonyms and CAS numbers to help you find the best supplier. The use of synonyms and CAS numbers can be helpful in identifying potential suppliers, but it is crucial to note that they might not always indicate the exact same product. It is important to confirm the product details with the supplier before making a purchase to ensure that it meets your requirements.
Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty